Cell and gene therapy

#CAR-T #Cell and gene therapy #Cell therapy #Financing #In vivo #Investment

$175M financing will support development of in vivo CAR-T therapies

Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing. The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309 delivers an… Read More

#Business & Investment #News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

#Asgard Therapeutics #Cell and gene therapy #Financing #Immuno-oncology #In vivo

€30m raised for first-in-class in vivo cell reprogramming platform

Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming… Read More

#Business & Investment #News

#Cell and gene therapy #Drug development #Drug discovery #Guide

DDW Cell & Gene Therapy Guide 2024

Download the exclusive Guide and read about: Where is the global innovation in CGT and what opportunities is it creating? What does the CGT sector need to overcome challenges and get to market faster? Does the CGT sector have the skills required to ensure future success and of not, how… Read More

#DDW eBooks #DDW Guides

Business acquisition
#Cell and gene therapy #Genetic engineering #Ginkgo Bioworks #Patch Biosciences #RNA #Therapeutics

Ginkgo acquires machine learning biotech Patch Biosciences

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services.  Ginkgo provides R&D services across industries, including in biopharma, and will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new… Read More

#News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

New DDW Highlights podcast: 26 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a breakthrough for advanced therapies, this week saw the FDA approve the first… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

This week in drug discovery (19-23 February) 

News round-up for 19-23 February by DDW Digital Content Editor Diana Spencer. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Webinar

DDW webinar: Achieve future success in cell and gene therapy

Hosted by DDW and sponsored by Astrea Bioseparations “Cell and gene therapies – how can market growth be sustained to maximise on opportunities” – will be free to attend on 28 February at 7AM PST / 10AM EST / 3PM GMT / 4PM CET.  … Read More

#News

Cell and gene therapy
#Cell and gene therapy #MIP Discovery #Seed funding

£7M to drive commercialisation in cell and gene therapies (CGTs) 

MIP Discovery has closed a £7 million GBP (~$9 million USD) Series A financing round, which enables the company to refocus its mission on improving the downstream processing of cell and gene therapies (CGTs), to accelerate widespread adoption of these potentially life-changing medicines.    MIP Discovery develops non-biological… Read More

#News

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Webinar

DDW webinar: Global opportunities in cell and gene therapy

Hosted by DDW and sponsored by Astrea Bioseparations “Cell and gene therapies – how can market growth be sustained to maximise on opportunities” – will be free to attend on 28 February at 7AM PST / 10AM EST / 3PM GMT / 4PM CET.  … Read More

#News

Blood samples in lab
#Blood cancer #CAR-T #Cell and gene therapy #Elicera Therapeutics #Phase I trial #Swedish Medical Products Agency

CAR-T therapy for B-cell lymphoma enters trials in Sweden

Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More

#Cancer Research #News

UK Department of Education
#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult #UK government

UK’s Education Secretary joins CGT Catapult to celebrate apprentices 

The UK’s Education Secretary Gillian Keegan attended a meeting with the Cell and Gene Therapy Catapult (CGT Catapult) to discuss the role of apprenticeships in the advanced therapies industry.  The meeting, which took place at Teesside University’s National Horizons Centre in Darlington during National Apprenticeship Week, highlighted how apprenticeships are… Read More

#News #Regulatory

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy #Webinar

Cell & gene therapies: How can market growth be sustained to maximise on opportunities?

In this on-demand webinar, hosted by DDW and sponsored by Astrea Bioseparations, learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist… Read More

Webinar date:
Sponsored by Astrea Bioseparations
#Webinars

Adenovirus
#AAV #Cell and gene therapy #Gene delivery #Gene therapy #Roundtable

Guide to using AAV vectors in gene therapy

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for… Read More

#Exclusive Content